TY - JOUR
T1 - Interferon priming enables cells to partially overturn the SARS coronavirus-induced block in innate immune activation
AU - Kuri, Thomas
AU - Zhang, Xiaonan
AU - Habjan, Matthias
AU - Martínez-Sobrido, Luis
AU - García-Sastre, Adolfo
AU - Yuan, Zhenghong
AU - Weber, Friedemann
PY - 2009/11/1
Y1 - 2009/11/1
N2 - SARS coronavirus (SARS-CoV) is known to efficiently suppress the induction of antiviral type I interferons (IFN-alpha/beta) in non-lymphatic cells through inhibition of the transcription factor IRF-3. Plasmacytoid dendritic cells, in contrast, respond to infection with production of high levels of IFNs. Here, we show that pretreatment of non-lymphatic cells with small amounts of IFN-alpha (IFN priming) partially overturns the block in IFN induction imposed by SARS-CoV. IFN priming combined with SARS-CoV infection substantially induced genes for IFN induction, IFN signalling, antiviral effector proteins, ubiquitination and ISGylation, antigen presentation and other cytokines and chemokines, whereas each individual treatment had no major effect. Curiously, however, despite this typical IFN response, neither IRF-3 nor IRF-7 was transported to the nucleus as a sign of activation. Taken together, our results suggest that (i) IFN, as it is produced by plasmacytoid dendritic cells, could enable tissue cells to launch a host response to SARS-CoV, (ii) IRF-3 and IRF-7 may be active at subdetectable levels, and (iii) SARS-CoV does not activate IRF-7.
AB - SARS coronavirus (SARS-CoV) is known to efficiently suppress the induction of antiviral type I interferons (IFN-alpha/beta) in non-lymphatic cells through inhibition of the transcription factor IRF-3. Plasmacytoid dendritic cells, in contrast, respond to infection with production of high levels of IFNs. Here, we show that pretreatment of non-lymphatic cells with small amounts of IFN-alpha (IFN priming) partially overturns the block in IFN induction imposed by SARS-CoV. IFN priming combined with SARS-CoV infection substantially induced genes for IFN induction, IFN signalling, antiviral effector proteins, ubiquitination and ISGylation, antigen presentation and other cytokines and chemokines, whereas each individual treatment had no major effect. Curiously, however, despite this typical IFN response, neither IRF-3 nor IRF-7 was transported to the nucleus as a sign of activation. Taken together, our results suggest that (i) IFN, as it is produced by plasmacytoid dendritic cells, could enable tissue cells to launch a host response to SARS-CoV, (ii) IRF-3 and IRF-7 may be active at subdetectable levels, and (iii) SARS-CoV does not activate IRF-7.
KW - Animals
KW - Cell Line
KW - Cell Nucleus/chemistry
KW - Chlorocebus aethiops
KW - Cytokines/metabolism
KW - Humans
KW - Interferon Regulatory Factor-3/metabolism
KW - Interferon Regulatory Factor-7/metabolism
KW - Interferon-alpha/immunology
KW - Protein Transport
KW - SARS Virus/immunology
U2 - 10.1099/vir.0.013599-0
DO - 10.1099/vir.0.013599-0
M3 - Article
C2 - 19625461
SN - 0022-1317
VL - 90
SP - 2686
EP - 2694
JO - Journal of General Virology
JF - Journal of General Virology
IS - Pt 11
ER -